EP12.01. Evaluation of the LITE-Risk Prognostic Model in Consolidation Durvalumab and Osimertinib-Treated NSCLC - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Amanda Gibson
Meta Tag
Speaker Amanda Gibson
Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2
LITE-Risk prognostic model
metastatic non-small cell lung cancer
consolidation durvalumab
first-line osimertinib
lactate dehydrogenase
derived neutrophil-to-lymphocyte ratio
performance status
Glans-Look Lung Cancer Research Database
immune checkpoint inhibitors
EGFR-mutation positive disease
Powered By